COGT

Cogent Biosciences, Inc.

8.76 USD
-0.03 (-0.34%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cogent Biosciences, Inc. stock is up 16.96% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 June’s closed higher than May. 67% of analysts rate it a buy.

About Cogent Biosciences, Inc.

Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis.

  • HC Wainwright & Co.
    Mon Jun 17, 06:35
    buy
    confirm
  • Needham
    Mon Jun 17, 05:42
    buy
    confirm
  • Wedbush
    Fri May 24, 09:53
    hold
    confirm